WuXi AppTec subsidiary, STA Pharmaceutical, has signed a supply agreement with biopharma company TESARO.
The five year agreement will see STA provide supply materials for the recently launched ZEJULA – an orally active PARP inhibitor for the treatment of ovarian cancer.
The treatment was approved for epithelial ovarian, fallopian tube or primary peritoneal cancer by the US FDA in March, and is now available to patients in the USA.
This agreement follows a successful multiple-year development and clinical manufacturing arrangement with TESARO, and assisting with the expedited New Drug Application submission and final approval by FDA.
ZEJULA is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival in women with recurrent ovarian cancer.